Turn Therapeutics (NASDAQ:TTRX) Trading 9.5% Higher – Still a Buy?

Turn Therapeutics Inc. (NASDAQ:TTRX)’s stock price traded up 9.5% on Wednesday . The stock traded as high as $5.97 and last traded at $5.53. 61,128 shares changed hands during mid-day trading, a decline of 6% from the average session volume of 64,995 shares. The stock had previously closed at $5.05.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Turn Therapeutics has an average rating of “Hold” and a consensus target price of $8.00.

Turn Therapeutics Trading Up 9.5%

The company has a current ratio of 2.23, a quick ratio of 2.23 and a debt-to-equity ratio of 0.97. The firm has a market cap of $164.74 million and a price-to-earnings ratio of -29.11. The firm’s 50-day moving average is $4.20 and its 200-day moving average is $3.90.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Turn Therapeutics

Several institutional investors have recently made changes to their positions in TTRX. Millennium Management LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $377,000. Wellington Shields & Co. LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $259,000. XTX Topco Ltd bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $99,000. Brown Brothers Harriman & Co. bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $93,000. Finally, HighTower Advisors LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $78,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.